鲁索替尼乳膏(Ruxolitinib cream)在哪里买比较靠谱

Ruxolitinib cream cream), as an innovative Janus kinase (JAK) inhibitor, has attracted widespread attention in the field of dermatology treatment in recent years. The drug is approved by the U.S. Food and Drug Administration (FDA) for the short-term and discontinuous long-term treatment of mild-to-moderate atopic dermatitis (AD) in patients 12 years of age and older, and has shown potential in the treatment of autoimmune skin diseases such as vitiligo and psoriasis.

Reliable purchasing channels

1. International medical tourism: For qualified patients, international medical tourism is also a purchasing method worth considering. By going to India and other listed countries and buying directly from regular local pharmacies, you can not only ensure the quality of the medicines, but also experience local medical services first-hand. However, this method requires high time and money costs, so you need to choose carefully based on your own circumstances.

2. Transnational e-commerce platforms: With the rise of cross-border e-commerce, some multinational e-commerce platforms have also begun to provide overseas drug purchase services. These platforms usually cooperate with regular overseas pharmacies to provide multiple versions of ruxolitinib cream for patients to choose from. When purchasing, it is recommended to carefully screen the merchants, check their reviews and reputation, and consult the platform customer service to understand the source and transportation method of the drugs.

Clinical trial process and results

Clinical trial process: The clinical trial of ruxolitinib cream has undergone rigorous scientific evaluation. Among them, two randomized, double-blind, excipient-controlled phase 3 clinical trials are particularly critical. These trials were designed to evaluate the efficacy of ruxolitinib cream at different doses in patients with atopic dermatitis. In the trial, patients were randomly divided into treatment groups receiving different doses of ruxolitinib cream and vehicle control groups. After a certain period of treatment, the improvement of symptoms of the patients was observed and recorded.

Clinical trial results: Compared with vehicle, the proportion of patients who received ruxolitinib cream at different doses after 8 weeks of treatment achieved the primary endpoint was significantly better than that of the control group. This result shows that ruxolitinib cream has significant efficacy in the treatment of atopic dermatitis, can significantly improve patients' rash and itching symptoms, and improve patients' quality of life. In addition, ruxolitinib cream has also shown certain potential in the treatment of autoimmune skin diseases such as vitiligo, further broadening its clinical application scope.

Although ruxolitinib cream is not yet on the market in China, patients may still obtain its therapeutic benefits by purchasing it through formal channels and following medical instructions. At the same time, we also hope that with the advancement of science and technology and the deepening of medical research, ruxolitinib cream can be launched in China as soon as possible, bringing good news to more patients. For patients with skin diseases, choosing appropriate treatment drugs and following medical instructions are the key to controlling the disease and improving quality of life